PT - JOURNAL ARTICLE AU - Gentile, I AU - Giaccone, A AU - Scirocco, MM AU - Di Brizzi, F AU - Cuccurullo, F AU - Silvitelli, M AU - Ametrano, L AU - Alfè, FA AU - Pietroluongo, D AU - Irace, I AU - Chiariello, MR AU - De Felice, N AU - Severino, S AU - Viceconte, G AU - Schiano Moriello, N AU - Maraolo, AE AU - Buonomo, AR AU - Scotto, R AU - , TI - Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study) AID - 10.1101/2024.06.07.24307681 DP - 2024 Jan 01 TA - medRxiv PG - 2024.06.07.24307681 4099 - http://medrxiv.org/content/early/2024/06/07/2024.06.07.24307681.short 4100 - http://medrxiv.org/content/early/2024/06/07/2024.06.07.24307681.full AB - Introduction Ritonavir-boosted nirmatrelvir (N/r) is an antiviral which targets the main viral protease, administered to prevent the progression of SARS-CoV-2 infection in patients at high risk for severe COVID-19. We present a real-life case-control study evaluating the efficacy of N/r therapy in SARS-CoV-2 omicron variants positive outpatients in Campania region, Italy, with the aim of assessing the occurrence of three outcomes (hospital admission, admission in ICU and death) in cases and controls.Methods We enrolled SARS-CoV-2 positive subjects that came to our attention in Early antiviral treatment ambulatory of Infectious Disease ward of University Federico II of Naples, Italy from January 1st, 2022, to December 31st, 2022, during the first five days from symptoms occurrence. Patients were enrolled as cases or controls if they were treated with N/r or not treated at all, respectively.Results 1064 patients were included (cases: 423, controls: 1184). Cases showed a lower mortality compared with controls while no differences were observed for other outcomes. Vaccinated patients showed a lower mortality compared with non-vaccinated ones (0.5% vs 7.8%, p<0.001). After full-matching propensity score, N/r reduced hospitalization rate only in unvaccinated patients. In contrast N/r significantly reduced mortality regardless of vaccination status.Conclusions Treatment with N/r has proven effective in reducing mortality among outpatients with SARS-CoV-2 infection during several omicron variant surges. The beneficial effect of N/r treatment in reducing progression is more pronounced in unvaccinated patients.Competing Interest StatementProf. IVAN GENTILE reports personal fees from MSD, AbbVie, Gilead, Pfizer, GSK, SOBI, Nordic/Infecto Pharm, Angelini and Abbott, as well as departmental grants from Gilead and support for attending a meeting from Janssen, outside the submitted work. All other authors have no competing interests to declare. Funding StatementThis study was funded by the Campania Region as part of the European Fund for Regional Development (Fondo Europeo Sviluppo Regionale - FESR) for 2014-2020, under the project titled <Impact of Early Anti-SARS-CoV-2 Treatment in Vaccinated Subjects on Clinical Progression and Onset of Long-COVID (SAVALO Study)>.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee "A.O.U. Federico II - A.O.R.N. Cardarelli" granted ethical approval for this work (protocol number 0015191, 22nd March 2023).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets generated and/or analysed during the current study, along with the Case Report Forms (CRFs), the written informed consent from case participants, and the records of the telephonic interviews conducted with control participants, including their verbal informed consent, are stored by the data manager at the Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Sergio Pansini 5, 80131, Naples, Italy. These can be retrieved and reviewed upon request by any relevant authority.